This is a non-randomized, open label, two-cohort, multi-institutional study to evaluate the
use of diarrheal management tools intended to facilitate timely intervention and treatment
modifications due to afatinib treatment-related diarrhea in patients with EGFR
mutations-positive adenocarcinoma of the lung. Patients in Cohort 1 will follow diarrhea
management. Patients in Cohort 2 will receive prophylactic loperamide starting the fist day
of afatinib treatment.